ACHIEVEMENTS & AWARDS
We've reached a few milestones in our journey. We're pretty proud of what we've achieved along the way.
1998
AFT Pharmaceuticals is founded in Auckland, New Zealand.
2005
Offices are opened in Australia.
2011
North Shore Business Awards: Winner of the Westpac Supreme Business Excellence Award and Winner of the Ministry of Science and Innovation Excellence in Design, Research & Development Award.
2012
Maxigesic, a world-first combination analgesic, invented and subsequently licensed to 42 countries.
The novel SURF technology to design the company’s revolutionary hand held nebuliser is licensed.
2013
AFT Pharmaceuticals is granted Early Point Project (EPP) status for an orphan drug manufacturing and export hub based in Malaysia.
Offices are opened in Malaysia, and a branch office in Singapore.
Callaghan Innovation (New Zealand government agency) awards AFT Pharmaceuticals a Technology Development Grant to assist with R&D expenditure up to $3.85M (2013)
2014
Discovery of major formulation error in global cold and flu products published in the New England Journal of Medicine.
Capital Royalty (US) and Milford Asset Management (NZ) collectively invested US$12M in equity into Pharmaceuticals.
Maxigesic is registered in Europe.
2015
A pivotal clinical study in the USA and NZ is completed that forms the basis of AFT’s first filing with the United States Food and Drug Administration.
2017
Maxigesic became licensed in 124 countries worldwide
2018
AFT Pharmaceuticals made the top 1000 fast-growing companies list in the Asia-Pacific region.
